Last reviewed · How we verify
TT
TT is a Viral vector vaccine Biologic drug developed by CanSino Biologics Inc.. It is currently FDA-approved for COVID-19 prevention (marketed in multiple countries). Also known as: Tolterodine tartrate.
TT is a recombinant adenovirus type 5 vector-based vaccine that expresses the SARS-CoV-2 spike protein to elicit immune responses against COVID-19.
Here's a 2-sentence factual summary of TT based on the provided facts: TT refers to a genetic variant, as it is associated with point-of-care genetic testing in the context of STEMI treatment, according to ClinicalTrials.gov. The specific conditions and interventions studied in relation to TT are not explicitly stated in the provided facts, but TT is mentioned in relation to STEMI treatment in a clinical trial.
At a glance
| Generic name | TT |
|---|---|
| Also known as | Tolterodine tartrate |
| Sponsor | CanSino Biologics Inc. |
| Drug class | Viral vector vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
TT (also known as Convidecia or Ad5-nCoV) uses a replication-incompetent adenovirus serotype 5 as a viral vector to deliver genetic instructions for producing the SARS-CoV-2 spike protein. This triggers both cellular and humoral immune responses, enabling the body to recognize and neutralize the virus upon exposure. The vaccine can be administered as a single dose or in a prime-boost regimen.
Approved indications
- COVID-19 prevention (marketed in multiple countries)
Common side effects
- Injection site pain or swelling
- Fever
- Fatigue
- Headache
- Myalgia
Key clinical trials
- Teletherapy in Children Who Are Deaf and Hard of Hearing (NA)
- IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study (PHASE2)
- FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial (PHASE3)
- Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia (PHASE2)
- Non-Invasive Spinal Cord Stimulation After Injury (NA)
- AI-Driven Digital Self-Assessment Framework for Preclinical Tooth Preparation (NA)
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (PHASE3)
- Hemithyroidectomy or Total-Thyroidectomy in 'Low-risk' Thyroid Cancers (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TT CI brief — competitive landscape report
- TT updates RSS · CI watch RSS
- CanSino Biologics Inc. portfolio CI
Frequently asked questions about TT
What is TT?
How does TT work?
What is TT used for?
Who makes TT?
Is TT also known as anything else?
What drug class is TT in?
What development phase is TT in?
What are the side effects of TT?
What does TT target?
Related
- Drug class: All Viral vector vaccine drugs
- Target: All drugs targeting SARS-CoV-2 spike protein
- Manufacturer: CanSino Biologics Inc. — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for COVID-19 prevention (marketed in multiple countries)
- Also known as: Tolterodine tartrate
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing